. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Schizophr Res. 2014 Jun 10;158(0):45–51. doi: 10.1016/j.schres.2014.05.017

Table 3.

Timing of initial positive and non-specific symptom onset.

		Positive symptoms (39 CHR, 37 FES)	Non-specific symptoms (38 CHR, 37 FES)	First symptom (either) (40 CHR, 40 FES)
CHR	Childhood	11 (28.2%)	14 (38.9%)	19 (47.5%)
	Adolescence	14 (35.9%)	13 (36.1%)	14 (35.0%)
	Adulthood	14 (35.9%)	9 (25.0%)	7 (17.5%)
FES	Childhood	7(18.9%)	13 (35.1%)	15 (37.5%)
	Adolescence	10 (27.0%)	8 (21.6%)	8 (20.0%)
	Adulthood	20 (54.1%)	16 (43.2%)	17 (42.5%)
Chi-Square		2.564, p = 0.278	3.174, p = 0.204	6.274, p = 0.043

CHR = clinical high risk; FES = first episode schizophrenia. Counts represent the frequency of participants for whom the given symptom type was reported to have onset within the specified developmental stage (counting only 9 core SIPS symptoms for the first two columns and in column 3, including all 19 symptoms for CHR and acute and P5 onset for FES). “Lifetime” onsets counted as childhood for all columns. Twenty-six (65%) of FES and 20(50%) of CHR reported positive and non-specific symptom onsets within the same developmental period. Differences in distributions by group of p < 0.05 are in bold.